pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 3·1 min read
save

Eli Lilly says its GLP-1 weight loss shot and pill now covered for millions of Americans

Jun 3, 2026·read at Endpoints ↗Positive

Eli Lilly announced that its GLP-1 based weight-loss injection and oral medication have been added to the formularies of the three largest pharmacy benefit managers. The company said this move makes the treatments available to millions of Americans through employer health plans.

The inclusion by the major PBMs is presented as a key step toward broader employer coverage of GLP-1 therapies, which have been in high demand for weight management.

Analysts note that while the coverage expansion is positive for patient access, further negotiations and cost considerations will influence how widely employers adopt these drugs.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “What it will take for more employer GLP-1 coverage”

read at Endpoints ↗
77 words · retrieved Jun 3
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ELI LILLY CO2LILLY2
topics
GLP-1 receptor4Obesity2Small Molecule

related stories

  • Aug 5Lilly, FDA retatrutide biologic dispute comes to a head as submission nearsBioSpace
  • Aug 5Lilly climbs, Novo falls as obesity drug battle intensifiesBioPharma Dive
  • Aug 5Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1BioSpace
  • Aug 5Novo CEO sees innovation as a matter of survival amid pipeline setbacksBioSpace
  • Aug 4Novo dips 6% on Wegovy pill stumble despite Q2 earnings beatBioSpace